Yihai Cao - Curriculum Vitae#

  • 1993 - 1996 Postdoc, Harvard Medical School, Laboratory of Cancer Biology and Vascular Biology (Dr. Judah Folkman’s Laboratory), Department of Surgery and Cell Biology, Harvard Medical School and Children's Hospital, Boston, Mass. USA
  • 1993 Ph.D. in Cell Biology and Cancer Research, the Ludwig Institute-Karolinska Institutet, Stockholm, Sweden
  • 1988 - 1993 Ph.D. study, The Ludwig Institute for Cancer Research, Karolinska Institutet
  • 1986 - 1988 Visiting Scientist, the Laboratory of Molecular Biology, Ludwig Institute for Cancer Research, Bern Branch, Switzerland
  • 1983 - 1986 Institute of Hematology, Chinese Academy of Medical Sciences, China
  • 1978 - 1983 Study clinical medicine at the Shandong Medical College
  • Doctoral Degrees: 1) Ph.D. in Medical Sciences-Cell and Molecular Biology 1993, Karolinska Institutet; 2) hM.D., Copenhagen University, Denmark. 2006

Competitive Grants:

ERC advanced research grant; EU FP7 Metoxia; EU FP6 (Vascuplug); Human Frontier Science Program (HFSP); the NOVO Nordisk Foundation advanced grant.

Main supervisor for 14 Ph.D. students who received their Ph.D; currently - 2 Ph.D. students; Co-supervisor for 10 Ph.D students; 10 current Postdocs; Mentor for more than 40 postdocs and guest scientists.

Invited speaker at more than 100 international conferences, including: AACR conference, Gordon conference, OOTR conference, Charing Cross Symposium, European Angiogenesis Meeting, Kloster Seeon conference, and the ESF.

Editorial Board:

Vascular Cell, editor-in-chief; a member of editorial board for several journals.

Scientific Committee and Grant Review:

INSERM, France; CNR, Italy; MRC, UK; GRF, Germany; AIRC, Italy; ERC-starting grant panel member, Belgium; INCA, France; SNSF, Switzerland; FWO, Belgium; The Chinese NSF; ISF, Israel; Singapore Biomedical Research Council; A*STAR, Singapore

Holder of 60 internationally approved and published patents related to inventions in angiogenesis for disease therapy.

Founder of Biotech Companies:

Clanotech (2005-present) Development of novel antiangiogenic drugs for treatment of ocular disease (Karolinska Development); Swenora (2001-present) Development of new therapeutics for treatment of spinal cord injury

Imprint Privacy policy « This page (revision-5) was last changed on Tuesday, 18. December 2018, 11:42 by System
  • operated by